Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (245K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
Powles TJ, Coombes RC, Smith IE, Jones JM, Ford HT, Gazet JC. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1980 Mar 15;1(8168 Pt 1):580–582.[PubMed]
Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985 Jun;3(6):818–826.[PubMed]
Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep. 1986 Feb;70(2):261–266.[PubMed]
Price LA, Hill Bridget T. Breast cancer trials—a new initiative. Br Med J (Clin Res Ed) 1981 Feb 14;282(6263):b563–563.[PMC free article]
Baum Michael. Breast cancer trials—a new initiative. Br Med J (Clin Res Ed) 1981 Feb 14;282(6263):c563–564.[PMC free article]
Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988 Feb 18;318(7):404–407.[PubMed]
Henderson IC. Adjuvant therapy for breast cancer. N Engl J Med. 1988 Feb 18;318(7):443–444.[PubMed]
Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press